贝伐单抗与伊立替康用于复发性少突胶质细胞瘤 - Suppr

Suppr

超能文献

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

作者信息

Chamberlain Marc C

出版信息

Neurology. 2010 Jan 12;74(2):181. doi: 10.1212/WNL.0b013e3181c775e3.

DOI:10.1212/WNL.0b013e3181c775e3

PMID:20065257

Abstract

摘要

相似文献

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

Neurology. 2010 Jan 12;74(2):181. doi: 10.1212/WNL.0b013e3181c775e3.

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

Neurology. 2009 May 5;72(18):1601-6. doi: 10.1212/WNL.0b013e3181a413be.

Avastin: more questions than answers. .

J Neurosurg. 2012 Feb;116(2):336-40; discussion 340. doi: 10.3171/2011.8.JNS111107. Epub 2011 Oct 28.

Topoisomerase I inhibitors for the treatment of brain tumors.

Expert Rev Anticancer Ther. 2008 May;8(5):707-16. doi: 10.1586/14737140.8.5.707.

Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.

Br J Cancer. 2006 Nov 20;95(10):1424-31. doi: 10.1038/sj.bjc.6603390. Epub 2006 Oct 10.

Bevacizumab plus irinotecan in recurrent glioblastoma.

J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013. doi: 10.1200/JCO.2007.15.1605.

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

J Neurooncol. 2009 Feb;91(3):329-36. doi: 10.1007/s11060-008-9718-y. Epub 2008 Oct 25.

CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.

J Neurooncol. 2008 Sep;89(2):231-8. doi: 10.1007/s11060-008-9613-6. Epub 2008 May 15.

Bevacizumab: a treatment option for recurrent glioblastoma multiforme.

Ann Pharmacother. 2008 Oct;42(10):1486-90. doi: 10.1345/aph.1L030. Epub 2008 Sep 2.

Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.

Cancer. 2003 Mar 1;97(5):1276-84. doi: 10.1002/cncr.11187.

引用本文的文献

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

Onco Targets Ther. 2013 Apr 15;6:371-89. doi: 10.2147/OTT.S38628. Print 2013.

FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

Neuro Oncol. 2012 May;14(5):649-57. doi: 10.1093/neuonc/nos012. Epub 2012 Feb 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

Neurology. 2010 Jan 12;74(2):181. doi: 10.1212/WNL.0b013e3181c775e3.

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

Neurology. 2009 May 5;72(18):1601-6. doi: 10.1212/WNL.0b013e3181a413be.

Avastin: more questions than answers. .

J Neurosurg. 2012 Feb;116(2):336-40; discussion 340. doi: 10.3171/2011.8.JNS111107. Epub 2011 Oct 28.

Topoisomerase I inhibitors for the treatment of brain tumors.

Expert Rev Anticancer Ther. 2008 May;8(5):707-16. doi: 10.1586/14737140.8.5.707.

Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.

Br J Cancer. 2006 Nov 20;95(10):1424-31. doi: 10.1038/sj.bjc.6603390. Epub 2006 Oct 10.

Bevacizumab plus irinotecan in recurrent glioblastoma.

J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013. doi: 10.1200/JCO.2007.15.1605.

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

J Neurooncol. 2009 Feb;91(3):329-36. doi: 10.1007/s11060-008-9718-y. Epub 2008 Oct 25.

CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.

J Neurooncol. 2008 Sep;89(2):231-8. doi: 10.1007/s11060-008-9613-6. Epub 2008 May 15.

Bevacizumab: a treatment option for recurrent glioblastoma multiforme.

Ann Pharmacother. 2008 Oct;42(10):1486-90. doi: 10.1345/aph.1L030. Epub 2008 Sep 2.

Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.

Cancer. 2003 Mar 1;97(5):1276-84. doi: 10.1002/cncr.11187.

引用本文的文献

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

Onco Targets Ther. 2013 Apr 15;6:371-89. doi: 10.2147/OTT.S38628. Print 2013.

FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

Neuro Oncol. 2012 May;14(5):649-57. doi: 10.1093/neuonc/nos012. Epub 2012 Feb 29.